ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2018
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri).Brain and behavior · 2025Article
- Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study.Journal of neuroinflammation · 2023Article
- Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Subtypes of relapsing-remitting multiple sclerosis identified by network analysis.Frontiers in digital health · 2022Article
- Temporal trends of multiple sclerosis disease activity: Electronic health records indicators.Multiple sclerosis and related disorders · 2022Article
- Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design.BMC neurology · 2021Observational
- Serum antibodies to phosphatidylcholine in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Monitoring of radiologic disease activity by serum neurofilaments in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020Observational
- Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2020Article
- Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study.NPJ digital medicine · 2020Article
- Silent progression in disease activity-free relapsing multiple sclerosis.Annals of neurology · 2019Article
- Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.JAMA neurology · 2019Article
- Why monkeys do not get multiple sclerosis (spontaneously): An evolutionary approach.Evolution, medicine, and public health · 2018Review
- The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS).International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThere is a pressing need for robust longitudinal cohort studies in the modern treatment era of multiple sclerosis.
objectiveBuild a multiple sclerosis (MS) cohort repository to capture the variability of disability accumulation, as well as provide the depth of characterization (clinical, radiologic, genetic, biospecimens) required to adequately model and ultimately predict a patient's course.
methodsSerially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) is an international multi-center, prospectively enrolled cohort with over a decade of comprehensive follow-up on more than 1000 patients from two large North American academic MS Centers (Brigham and Women's Hospital (Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB; BWH)) and University of California, San Francisco (Expression/genomics, Proteomics, Imaging, and Clinical (EPIC))). It is bringing online more than 2500 patients from additional international MS Centers (Basel (Universitätsspital Basel (UHB)), VU University Medical Center MS Center Amsterdam (MSCA), Multiple Sclerosis Center of Catalonia-Vall d'Hebron Hospital (Barcelona clinically isolated syndrome (CIS) cohort), and American University of Beirut Medical Center (AUBMC-Multiple Sclerosis Interdisciplinary Research (AMIR)). RESULTS AND
conclusionWe provide evidence for harmonization of two of the initial cohorts in terms of the characterization of demographics, disease, and treatment-related variables; demonstrate several proof-of-principle analyses examining genetic and radiologic predictors of disease progression; and discuss the steps involved in expanding SUMMIT into a repository accessible to the broader scientific community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.